Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia

Archives of General Psychiatry

Volumn 60, Issue 3, 2003, Pages 311-319

  Koh, Phil Ok ^a   Bergson, Clare ^b   Undie, Ashiwel S ^a   Goldman Rakic, Patricia S ^c   Lidow, Michael S ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCYON; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE D1 RECEPTOR INTERACTING PROTEIN; FILAMIN; FILAMIN A; HALOPERIDOL; SPINOPHILIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; DOPAMINERGIC SYSTEM; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NONHUMAN; PATHOGENESIS; PREFRONTAL CORTEX; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RHESUS MONKEY; SCHIZOPHRENIA; SECOND MESSENGER; SLOT BLOT HYBRIDIZATION; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BLOTTING, WESTERN; CELL COUNT; CONTRACTILE PROTEINS; DEPRESSIVE DISORDER; FEMALE; FUNCTIONAL LATERALITY; HALOPERIDOL; HUMANS; MACACA MULATTA; MALE; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS; NERVE TISSUE PROTEINS; NEUROGLIA; NEURONS; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE D1; SCHIZOPHRENIA; UP-REGULATION;

EID: 0037335880     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.60.3.311     Document Type: Article

References (58)

1. Laruelle M. Imaging dopamine transmission in schizophrenia: a review and meta analysis. Q J Nucl Med. 1998;42:211-221.
2. Emilien G, Maloteaux JM, Geurts M, Owen MJ. Dopamine receptors and schizophrenia: contribution of molecular genetics and clinical neuropsychology. Int J Neuropsychopharmacol. 1999;2:197-227.
3. Soares JC, Innis RB. Neurochemical brain imaging investigations of schizophrenia. Biol Psychiatry. 1999;46:600-615.
4. Copolov D, Crook J. Biological markers and schizophrenia. Aust N Z J Psychiatry. 2000;34(suppl):S108-S112.
5. Bennett MR. Monoaminergic synapses and schizophrenia: 45 years of neuroleptics. J Psychopharmacol. 1998;12:289-304.
6. Lidow MS, Williams GV, Goldman-Rakic PS. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol Sci. 1998;19:136-140.
7. Lidow MS. General overview of contemporary antipsychotic medications. In: Lidow MS, ed. Neurotransmitter Receptors in Actions of Antipsychotic Medications. Boca Raton, Fla: CRC Press LLC; 2000:17-29.
8. Lidow MS, Goldman-Rakic PS. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci U S A. 1994;91:4353-4356.
9. Lidow MS, Elsworth JD, Goldman-Rakic PS. Downregulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther. 1997;281:597-603.
10. Kurumaji A, Okubo Y. D1 dopamine receptors, schizophrenia, and antipsychotic medications. In: Lidow MS, ed. Neurotransmitter Receptors in Actions of Antipsychotic Medications. Boca Raton, Fla: CRC Press LLC; 2000:65-78.
11. Shaw P, Pilowsky LS. Probing cortical sites of antipsychotic drug action with in vivo receptor imaging. Behav Neurol. 2001;12:3-9.
12. Martin MW, Scott AW, Johnston DE Jr, Griffin S, Luedtke RR. Typical antipsychotics exhibit inverse agonist activity at rat dopamine D1-like receptors expressed in Sf9 cells. Eur J Pharmacol. 2001;420:73-82.
13. Goldman-Rakic PS. Prefrontal cortical dysfunction in schizophrenia: the relevance of working memory. In: Carrol BL, Barrett JE, eds. Psychopathology and the Brain. New York, NY: Raven Press; 1991:1-23.
14. Perlstein WM, Carter CS, Noll DC, Cohen JD. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry. 2001;158:1105-1113.
15. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 1995;376:572-575.
16. Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science. 2000;287:2020-2022.
17. Goldman-Rakic PS, Muly EC, Williams GV. D1 receptors in prefrontal cells and circuits. Brain Res Rev. 2000;31:295-301.
18. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 1991;251:947-950.
19. Arnsten AFT, Cai JX, Murphy BL, Goldman-Rakic PS. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology. 1994;116:143-151.
20. Goldman-Rakic PS. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry. 1999; 46:650-661.
21. Bunney WE, Bunney BG. Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Res Rev. 2000;31:138-146.
22. Palermo-Neto J. Dopaminergic systems: dopamine receptors. Psychiatr Clin North Am. 1997;20:705-721.
23. Sidhu A, Niznik HB. Coupling of dopamine receptor subtypes to multiple and diverse G proteins. Int J Dev Neurosci. 2000;18:669-677.
24. Oldenhof J, Vickery R, Anafi M, Oak J, Ray A, Schoots O, Pawson T, von Zastrow M, Van Tol HHM. SH3 binding domains in the dopamine D4 receptor. Biochemistry. 1998;37:15726-15736.
25. Smith FD, Oxford GS, Milgram SL. Association of the D2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein. J Biol Chem. 1999;274:19894-19900.
26. Lezcano N, Mrzljak L, Eubanks S, Levenson R, Goldman-Rakic P, Bergson C. Dual signaling regulated by calcyon, a D1 dopamine receptor interacting protein. Science. 2000;287:1660-1664.
27. Li M, Bermak JC, Wang ZW, Zhou QY. Modulation of dopamine D(2) receptor signaling by actin-binding protein (ABP-280). Mol Pharmacol. 2000;57: 446-452.
28. Lidow MS, Roberts A, Zhang L, Koh P, Lezcano N, Bergson C. Receptor crosstalk protein, calcyon, regulates affinity state of dopamine D1 receptors. Eur J Pharmacol. 2001;427:187-193.
29. Lin R, Karpa K, Kabbani N, Goldman-Rakic P, Levenson R. Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A. Proc Natl Acad Sci U S A. 2001;98:5258-5263.
30. Lezcano N, Bergson C. D1/D5 dopamine receptors stimulate intracellular calcium release in primary cultures of neocortical and hippocampal neurons. J Neurophysiol. 2002;87:2167-2175.
31. Weinberger DR, Aloia MS, Goldberg TE, Berman KF. The frontal lobes and schizophrenia. J Neuropsychiatry Clin Neurosci. 1994;6:419-427.
32. Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain. 1999;122:593-624.
33. Brodmann K. Localization in the Cerebral Cortex. Gray LJ, trans-ed. London, England: Smith-Gordon; 1994.
34. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation brain collection and neuropathology consortium. Schizophr Res. 2000;44: 151-155.
35. Knable MB, Torrey EF, Webster MJ, Bartko JJ. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull. 2001;55:651-659.
36. Arana GW, Hyman SE, Rosenbaum JF. Handbook of Psychiatric Drug Therapy. 4th ed. New York, NY: Lippincott Wiliams & Wikins; 2000.
37. Aakhus AM, Wilkinson JM, Solum NO. Binding of human platelet glycoprotein Ib and actin to fragments of actin-binding protein. Thromb Haemost. 1992;67: 252-257.
38. Allen PB, Ouimet CC, Greengard P. Spinophilin, a novel protein phosphatase 1 binding protein localized to dendritic spines. Proc NatlAcad Sci U S A. 1997;94: 9956-9961.
39. Lidow MS, Song ZM, Castner SA, Allen PB, Greengard P, Goldman-Rakic PS. Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex. Biol Psychiatry. 2001; 49:1-12.
40. Selemon LD, Lidow MS, Goldman-Rakic PS. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol Psychiatry. 1999;46:161-172.
41. Gorlin JB, Yamin R, Egan S, Stewart M, Stossel TP, Kwiatkowski DJ, Hartwig JH. Human endothelial actin-binding protein (ABP-280, nonmuscle filamin): a molecular leaf spring. J Cell Biol. 1990;111:1089-1105.
42. Cotter D, Mackay D, Ghana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex. 2002;12: 386-394.
43. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry. 1995;52:805-818.
44. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45: 1085-1098.
45. Raikowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry. 2001;49:741-752.
46. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 1997;385:634-636.
47. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci. 2002; 22:3708-3719.
48. Karlsson P, Farde L, Halldin C, Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry. 2002; 159:761-767.
49. Mirnics K, Middleton FA, Lewis DA, Levitt P. Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci. 2001;24:479-486.
50. Wallace MA, Claro E. Transmembrane signaling through phospholipase C in human cortical membranes. Neurochem Res. 1993;8:139-145.
51. Jope RS, Song L, Grimes CA, Pacheco MA, Dilley GE, Li X, Meltzer HY, Overholser JC, Stockmeier CA. Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence. J Neurochem. 1998;70:763-771.
52. Mamelak M, Chiu S, Mishra RK. High- and low-affinity states of dopamine D1 receptors in schizophrenia. Eur J Pharmacol. 1993;233:175-176.
53. Vianna MR, Barros DM, Silva T, Choi H, Madche C, Rodrigues C, Medina JH, Izquierdo I. Pharmacological demonstration of the differential involvement of protein kinase C isoforms in short- and long-term memory formation and retrieval of one-trial avoidance in rats. Psychopharmacology (Berl). 2000;150:77-84.
54. Birnbaum SG, Davis D, Gobeske K, Taylor JR, Arnsten AFT. The intracellular signaling mechanisms mediating stress-induced prefrontal cortex dysfunction in rats. Soc Neurosci Abstr. 2001;27:1404.
55. Krauss G. Biochemistry of Signal Transduction and Regulation. 1st ed. New York, NY: John Wiley & Sons Inc; 2000.
56. Meador-Woodruff JH, Clinton SM, Davis, KL, Haroutunian V. Abnormalities of molecules associated with dopaminergic neurotransmission in the thalamus in schizophrenia [abstract]. Proc Am Coll Neuropsychopharmacol. 2001;40: 279.
57. Kaiya H. Second messenger imbalance hypothesis of schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 1992;46:33-38.
58. Strunecka A, Ripova D. What can the investigation of phosphoinositide signaling system in platelets of schizophrenic patients tell us? Prostaglandins Leukot Essent Fatty Acids. 1999;61:1-5.